Literature DB >> 15102562

A review of the treatment options for Huntington's disease.

Raphael M Bonelli1, Peter Hofmann.   

Abstract

Huntington's disease (HD) is an autosomal dominant, inherited, neuropsychiatric disease which gives rise to progressive motor, cognitive and behavioural symptoms. Its core pathology involves degeneration of the basal ganglia, in particular, the caudate and putamen, and is caused by a single autosomal gene coding for a mutated form of the protein, huntingtin. At the present time, the only treatment options available in HD are symptomatic. There are several substances available today for the treatment of chorea. Other neurological symptoms, such as dystonia, can be treated, but treatment is associated with a high risk of adverse events. Psychiatric symptoms, on the other hand, are often amenable to treatment and relief of these symptoms may provide significant improvement in quality of life.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15102562     DOI: 10.1517/14656566.5.4.767

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  9 in total

Review 1.  Differential vulnerability of neurons in Huntington's disease: the role of cell type-specific features.

Authors:  Ina Han; YiMei You; Jeffrey H Kordower; Scott T Brady; Gerardo A Morfini
Journal:  J Neurochem       Date:  2010-03-17       Impact factor: 5.372

Review 2.  Therapeutic approaches to Huntington disease: from the bench to the clinic.

Authors:  Nicholas S Caron; E Ray Dorsey; Michael R Hayden
Journal:  Nat Rev Drug Discov       Date:  2018-09-21       Impact factor: 84.694

Review 3.  Large animal models of neurological disorders for gene therapy.

Authors:  Christine Gagliardi; Bruce A Bunnell
Journal:  ILAR J       Date:  2009

Review 4.  Treatment of Huntington's disease.

Authors:  Samuel Frank
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

Review 5.  Advances in the pharmacological management of Huntington's disease.

Authors:  Samuel Frank; Joseph Jankovic
Journal:  Drugs       Date:  2010-03-26       Impact factor: 9.546

Review 6.  Nosology and Phenomenology of Psychosis in Movement Disorders.

Authors:  Malco Rossi; Nicole Farcy; Sergio E Starkstein; Marcelo Merello
Journal:  Mov Disord Clin Pract       Date:  2020-01-07

7.  Tetrabenazine: the first approved drug for the treatment of chorea in US patients with Huntington disease.

Authors:  Samuel Frank
Journal:  Neuropsychiatr Dis Treat       Date:  2010-10-05       Impact factor: 2.570

8.  Genistein improves 3-NPA-induced memory impairment in ovariectomized rats: impact of its antioxidant, anti-inflammatory and acetylcholinesterase modulatory properties.

Authors:  Esther T Menze; Ahmed Esmat; Mariane G Tadros; Ashraf B Abdel-Naim; Amani E Khalifa
Journal:  PLoS One       Date:  2015-02-12       Impact factor: 3.240

9.  Childhood-onset (Juvenile) Huntington's disease: A rare case report.

Authors:  Kailash Chandra Patra; Mukund Sudhir Shirolkar
Journal:  J Pediatr Neurosci       Date:  2015 Jul-Sep
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.